Dawnrays Pharmaceutical Holdings Ltd. reported audited consolidated earnings results for the year ended December 31, 2012. For the year, the company reported profit before tax of RMB 144,641,000 and profit attributable to owners of the parent of RMB 114,506,000 or RMB 0.1429 per diluted share on revenue of RMB 856,539,000 compared to profit before tax of RMB 179,187,000 and profit attributable to owners of the parent of RMB 146,307,000 or RMB 0.1826 per diluted share on revenue of RMB 1,081,044,000 reported a year ago. Cash flows from operating activities were RMB 203,624,000 compared to RMB 82,986,000 reported a year ago. The decrease in turnover and profit was mainly due to the decline in the group's sales of cephalosporin intermediates, bulk medicines and powder for injection, in comparison to the corresponding period last year. Return on net assets was 11.7%, compared to 15.9% for the last year. The Board recommends the payment of a final dividend of HKD 0.055 per share for the year ended 31 December 2012, amounting to the total sum of approximately HKD 44,033,000 (equivalent to approximately RMB 35,408,000), to the shareholders whose names appeared in the register of members as of 31 May 2013 subject to the approval of the shareholders at the forthcoming 2013 Annual General Meeting (the "2013 AGM"). Taking into consideration the interim dividend of HKD 0.015 per share, the total annual dividend distributed for the year is HKD 0.07 per share. 2013. The proposed final dividend is subject to approval of the shareholders at the 2013 AGM of the company to be held on 24 May 2013, is to be payable on 11 June 2013 to shareholders.

Dawnrays Pharmaceutical Holdings Ltd., Annual General Meeting, May 24, 2013., at 10:00 China Standard Time. Location: Plaza 1­2, Novotel Century Hong Kong Hotel. Agenda: To approve dividend for 2012; to receive and consider the audited consolidated financial statements and the reports of the directors and the auditors for the financial year ended 31 December 2012; to re-elect directors; to re-appoint auditors and to authorise the Board to fix their remuneration; to authorize the directors to allot, issue and deal with the unissued shares and to make or grant offers, agreements and options; to authorize the directors to purchase the shares; to authorize the directors to purchase or otherwise acquire shares in the capital of the Company on the Stock Exchange of Hong Kong Limited; and to consider other issues.

Dawnrays Pharmaceutical Holdings Ltd. announced that they will report fiscal year 2012 results on Mar 22, 2013